We retrospectively identified opportunistic CNS infections in 655 patients who had undergone allogeneic, syngeneic or autologous BMT or PBSCT between 1990 and 1997. Twenty-seven patients (4%) developed CNS infections. All CNS infections occurred in allogeneic BMT or PBSCT patients. The most common CNS infections were toxoplasma encephalitis (74%) and cerebral aspergillosis (18%). Furthermore, we identified one patient with candida encephalitis and one patient with viral encephalitis. Overall mortality of patients with opportunistic CNS infection was 67%. There were two different groups of toxoplasma encephalitis with a different appearance on MR imaging. The first group showed edema, but no gadolinium enhancement, whereas the second group exhibited typical MRI appearances with the exception of frequent hemorrhagic transformation. The first group had a significant shorter latency between BMT and onset of CNS infection (mean 45 days vs 180 days, P = 0.02), a significant higher daily dose of corticosteroids as treatment for graft-versus-host disease (GVHD) (P = 0.01), more severe GVHD and a higher mortality (71% vs 36%). This study shows that the most common CNS infections in our patient population are toxoplasma encephalitis and cerebral aspergillosis, that there are two distinct subgroups of toxoplasma encephalitis and that CNS infections occur after allogeneic BMT only. Keywords: CNS infection; cerebral toxoplasmosis; cerebral aspergillosis Both allogeneic and autologous BMT are associated with several neurologic complications secondary to the underlying disease and prolonged myelosuppression.
Infections are a major cause of morbidity and mortality and represent the most significant barrier to both immediate and long-term survival after BMT. 6, 7 CNS infections occurred mostly in patients who had undergone allogeneic BMT and are reported to occur in 3-8% of patients after allogeneic, syngeneic or autologous BMT. [1] [2] [3] [4] CMV encephalitis and cerebral aspergillosis are the most common CNS infections, whereas cerebral toxoplasmosis seems to be a rare condition. 2, 4 Fungi were isolated from brain abscesses in up to 90% of cases. Aspergillus species were the most prevalent fungi and Candida species were second in frequency. 8 Previous studies have preferentially focused on general neurological complications secondary to BMT and reviewed predominantly autopsy files. [2] [3] [4] In the present study, we retrospectively analyzed clinical data and re-evaluated MR imaging of patients with CNS infections after BMT to obtain cause, frequency, time of onset and clinical signs of these infections.
Patients and methods
From January 1990 to October 1997, 655 patients underwent allogeneic, syngeneic or autologous BMT or peripheral blood stem cell transplantation (PBSCT) at the University Clinic of Essen (basic characteristics see Table 1 ). Seventy-four patients received autologous BMT and/or autologous PBSCT (11%), whereas 571 patients were treated with allogeneic BMT and/or allogeneic PBSCT (87%). Syngeneic BMT and/or syngeneic PBSCT were performed in 10 patients (1%). The mean age of patients was 38.9 years (15-59 years). Underlying diseases were CML (n = 273, 42%), AML or ALL (together n = 238, 36%) and miscellaneous diseases such as plasmocytoma or myelodysplastic syndrome (n = 144, 22%). Clinical data and complications after BMT were routinely recorded in a database in the BMT department. Additional information was obtained from chart records of hospitalized patients and follow-up records in our outpatient clinic in the BMT department and in the neurological department. Data of magnet resonance (MR) imaging were kept in a database and images were saved as hard copies and on optical disks. We reviewed the records and MR imaging of all patients diagnosed as having CNS infections between BMT and death or the last follow-up visit. The diagnosis of CNS infection was confirmed by two or more of the following conditions: (1) autopsy or biopsy studies; and/or (2) typical neuroradiological images; (3) neuroradiological and clinical response to specific unidirectional antimicrobial chemotherapy; and/or (4) positive serology ( Table 2 ). The last condition only applied to cases of toxoplasma encephalitis, given the fact that all other CNS infections were confirmed by autopsy. 'Positive serology' was determined by: (1) positive IgM and/or positive IgG serum antibodies against Toxoplasma gondii; (2) negative Aspergillus and Candida antigen; and (3) negative CMV pp65 antigen. Patients with an uncertain diagnosis or a diagnosis of another secondary neurologic complication, as for example, metabolic encephalopathies or subdural hematoma due to BMT were excluded from the analysis. GVHD was a frequent accompanying disease in our patients and was diagnosed in 387 patients (59%). We graded the severity of this condition according to the involvement of skin, liver and gastrointestinal system by using the clinical classification described by Thomas et al. 9 Grade I GVHD was found in 194 patients (29.6% of all patients), grade II in 86 patients (13.1%) and grades III and IV in 107 patients (16.3%). All patients received variable doses of immunosuppressive drugs. To allow comparisons between different patient groups we calculated the mean corticosteroid dose with the following formula which accounts for the stronger glucocorticoid effect of methylprednisolone in comparison to prednisone: prednisone (mg) + [methylprednisolone (mg) ϫ 1.25]/n = mean corticosteroid dose/day.
Descriptive statistics of the main characteristics (age, underlying disease, type of infection, latency between onset of CNS infection and BMT, mean corticosteroid amount, severity of GVHD, leukocyte count) of the patients were performed. Continuous variables were compared by independent t-test using SPSS. Equal variances were not assumed in the t-test. Values below or above two standard deviations were excluded from comparison by means of the t-test.
Results
We identified 27 patients (4%) with opportunistic CNS infection from 655 patients who had undergone BMT or PBSCT. Basic characteristics of patients with identified CNS infection (females = 11, males = 15) are shown in Table 3 . Mean age was 38.2 years (Ϯ10.5 years). All CNS infections occurred in patients undergoing allogeneic BMT (n = 25) or allogeneic PBSCT (n = 2). Underlying diseases were CML (n = 15; 56%), ALL (n = 6; 22%), AML (n = 4; 15%), myelodysplastic syndrome (n = 1; 4%) and plasmocytoma (n = 1; 4%). In 12 patients autopsy or biopsy studies were available (44.4% of patients included). In our population, toxoplasma encephalitis was the most common opportunistic CNS infection. Twenty patients had toxoplasma encephalitis (74%), five patients aspergillus encephalitis (18%), one patient candida encephalitis (4%) and one patient viral encephalitis (4%). Two patients showed the criteria of GVHD grade 0, four patients had grade I, seven patients had grade II, seven patients had grade III and seven patients had grade IV. The leukocyte count at time of CNS infection was obtained from the chart records (unavailable in two patients). The mean leukocyte count of the remaining 25 patients was 4520 Ϯ 3086/l. Treatment for GVHD included variable doses of corticosteroids, cyclosporine, antithymocyte globulin and monoclonal antibodies. Overall mortality of patients with opportunistic CNS infections was 67% from time of BMT or PBSCT until October 1997 (n = 18/27).
Toxoplasma encephalitis
Toxoplasma encephalitis was diagnosed in 20 patients (four diagnoses confirmed by autopsy or biopsy studies, 16 diagnoses from neuroradiological and clinical criteria as described above). Cerebral toxoplasmosis occurred from day 14 to day 689 after BMT/PBSCT (median 72.5, mean 123 Ϯ 150). Clinical signs were focal and generalized seizures (n = 9), neuropsychological and cognitive disturbances (n = 7), headache (n = 5), focal cerebral signs (hemiparesis, hemianopia, ataxia, dysarthria) (n = 5), and impairment of consciousness (n = 4) ( Table 4 ). Serological findings of these patients are shown in Table 5 . For the MRI study MR images from 18 of 20 patients were available. Diagnoses of the remaining two patients were confirmed by autopsy studies. The overall mortality in the group of patients with toxoplasma encephalitis (not necessarily due to toxoplasma encephalitis) was 55% (11/20 patients). MR imaging of patients with toxoplasma encephalitis revealed two differing main features. There were patients with multiple areas of signal hyperintensity on T2-weighted images (T2WI) in supra-and infra-tentorial locations (Figure 1a) . ToI = type of infection; toxo = toxoplasma encephalitis; asperg = cerebral aspergillosis; candida = candida encephalitis; viral = viral encephalitis; ToT = type of transplantation; UD = underlying disease; I-BMT = interval between BMT and CNS infection in days; GVHD = graft-versus-host disease; S = skin; L = liver; GI = gastrointestinal; PR = prednisone in mg, CsA = cyclosporine A; SDH = methylprednisolone in mg or gram (g); OKT = monoclonal antibodies; ATG = antithymocyte globulin; ? = information at time of infection not available.
These lesions showed minimal space-occupying effects. On T1-weighted images (T1WI) they were hypointense or not visible at all and demonstrated no contrast enhancement (Figure 1b) . Another group of patients showed typical MRI appearance of toxoplasma encephalitis with multiple lesions on T1WI and T2WI and ring-enhancement with perifocal edema (Figure 2 ). In half of these patients lesions were hyperintense on non-contrast T1WI indicating hemorrhage ( Figure 3) . A comparison of the clinical characteristics of these two groups is shown in Table 6 .
Most common locations of the MRI lesions were subcortical white matter, basal ganglia and cerebellum. The first type of MRI appearance as described above was found in seven patients. The infection in these patients manifested itself from day 14 to day 75 (mean 45 Ϯ 22 days). Underlying diseases were AML (n = 1), ALL (n = 2), CML (n = 2), plasmocytoma (n = 1) and MDS (n = 1). Leukocyte counts were 1000-9700/l (mean 3733 Ϯ 3116/l) at the time of infection. GVHD was grade 0 in one patient (14%), grade I in one patient (14%), grade II in one patient (14%), grade III in one patient (14%) and grade IV in three patients (43%). Immunosuppressive therapy included prednisone (100-180 mg/day, n = 3), methylprednisolone (240-2000 mg/day, n = 4), cyclosporine (n = 6) and monoclonal antibodies (n = 1). Mean corticosteroid dose was 604 Ϯ 854 mg/day. Treatment for toxoplasma encephalitis was begun as soon as the diagnosis was clinically suspected using a standard therapy regimen with pyrimethamine (100 mg/day) and sulfadiazine (4-8 g/day). Five patients (71%) showed clinical and neuroradiological improvement after initiation of treatment. Two of the five patients who had shown improvement with specific therapy died later of heart failure and pneumonia, unrelated to the toxoplasma encephalitis. Overall mortality of these seven patients was 71% (5/7 patients).
The second MRI appearance with typical MRI appearance of toxoplasma encephalitis was found in 11 patients. The interval between BMT and onset of cerebral toxoplasmosis for these patients was between 62 and 689 days (mean 180 Ϯ 184.4 days). Underlying diseases were CML (n = 10) and AML (n = 1). The mean leukocyte count at the time of infection was 5370 Ϯ 2983/l (2000-9200/l). Immunosuppressive therapy included prednisone (5- Candida antigen = immunohemagglutination; Aspergillus antigen = latex agglutination; Cryptococcus antigen = enzyme-linked immunoassay; Toxoplasma: AGG = immunosorbent agglutination; IHA = immunohemagglutination, EIA = enzyme-linked immunoassay; NA = not available; pos = positive; neg = negative; I-BMT ϭ interval between BMT and CNS infection in days.
200 mg/day, n = 9), methylprednisolone (30-100 mg/day, n = 2), cyclosporine (n = 8) and monoclonal antibodies (n = 2). The mean corticosteroid amount was 89 Ϯ 70 mg/day. In this group GVHD was classified as grade I in three patients (28%), grade II in four patients (36%) and grade III in four patients (36%). Overall mortality of these 11 patients was 36% (4/11 patients).
Cerebral aspergillosis
The diagnosis of aspergillus encephalitis was made in five patients. All diagnoses were confirmed by autopsy studies. Time of onset of cerebral aspergillosis was at minimum day 39 and at maximum day 290 after BMT/PBSCT (median 110, mean 143 Ϯ 94). Neurological symptoms and signs were neuropsychological disturbances (n = 4), headache (n = 3), hemianopia (n = 3), focal and generalized seizures (n = 2), coma (n = 2) and hemiparesis (n = 1). The mean leukocyte count was 4160 Ϯ 3225/l. Grade I of GVHD was found in one patient (20%), grade III in one patient (20%) and grade IV in three patients (60%). Patients received immunosuppressive therapy with methylprednisolone (1-2 g/day, n = 3), prednisone (25-45 mg/day, n = 2) and cyclosporine (n = 3). MR images on T2WI revealed large lesions with an intermediate signal and with surrounding edema. In all patients ring-enhancement could be demonstrated ( Figure 4 ). In three of five patients we found a significant mass effect and in two patients lesions showed hemorrhagic transformation. Lesions were localized cortically, subcortically, in the basal ganglia and cerebellum. All patients died due to central nervous complications of cerebral aspergillosis. 
Candida encephalitis
We identified one patient with candida encephalitis. The diagnosis was confirmed by autopsy. The interval between BMT and the diagnosis of candida encephalitis was 24 days. The patient received 150 mg cyclosporine at the time of infection and had a leukocyte count of 4300/l. GVHD was not apparent. MR images showed multiple hypointense lesions on T1WI, ring-enhancement after gadolinium application and intermediate-signal lesions within surrounding high-signal on T2WI. The lesions were localized to the cerebellum and the basal ganglia. The patient died 19 days after onset of symptoms of respiratory failure.
Viral encephalitis
One patient died of brain stem hematoma probably due to a viral encephalitis, as revealed by autopsy. The underlying disease was CML. The interval between BMT and infection was 88 days. The patient had a leukocyte count of 3100/l at the time of infection. GVHD was grade III and the patient received immunosuppressive therapy with 1000 mg methylprednisolone per day and cyclosporine. Clinical signs were nystagmus, diplopia and impairment of consciousness. MR imaging revealed ill-defined hippocampal, cerebellar and brain stem hyperintense lesions on T2WI with hemorrhagic transformation on T1WI and intense gadolinium enhancement.
Discussion
CNS infections and metabolic encephalopathies are the most frequent neurologic complications following allogeneic BMT. [1] [2] [3] [4] [5] 10 The present study focused on the frequency and cause of opportunistic CNS infections in a large population of patients who had undergone BMT or PBSCT. A frequency of 4% of CNS infections after BMT or PBSCT in our population is comparable to that in former studies. Graus et al 4 reported an occurrence of 3% of CNS infections in allogeneic BMT patients, whereas Patchell et al 2 found 8% of CNS infections in an autopsy study. We found CNS infections only in patients who had undergone allogeneic BMT or PBSCT. This is in accordance with the study of Graus et al, 4 who compared neurologic complications after allogeneic and autologous BMT and identified no CNS infections in patients after autologous BMT. In the present study the overall mortality of patients with opportunistic CNS infection was 67%, which is comparable to the high mortality found in former studies. 4 In our series the most common infections were toxoplasma encephalitis and cerebral aspergillosis. This differs from the results in previous post-mortem and clinical studies, [1] [2] [3] [4] 8, 10 which reported CMV encephalitis and aspergillosis to be the most frequent cerebral infections.
One explanation for the fact that we did not identify patients with CMV encephalitis is the improvement in early diagnosis and management in the last years. In our hospital each patient was examined twice weekly for active CMV infection as indicated by markers of replication (pp65-antigen, polymerase chain reaction of virus-DNA) from day 20 to month 2 after BMT. Thereafter, pp65-antigen was sought monthly. In the event of active replication the patient received specific antiviral treatment. Clinical studies have shown that the use of CMV-negative blood products in transplantation if donor and patient lack CMV antibodies at the time of BMT, as well as prophylactic administration of acyclovir or ganciclovir to patients at high risk serve to reduce the incidence of systemic and of cerebral CMV infection. [11] [12] [13] Toxoplasma encephalitis occurs frequently in patients with acquired immunodeficiency syndrome (AIDS). [14] [15] [16] Prior to AIDS, fulminate necrotizing encephalitis due to toxoplasma infection was observed in patients with significant immunodeficiency such as collagen vascular disease, underlying malignancy, organ transplantation, and patients maintained on steroids, chemotherapy or radiation therapy. [17] [18] [19] It seemed to be a rare condition in BMT patients. Winston et al 6 (UCLA transplant group) reported one case only out of 60 patients after BMT. Patchell et al 2 described another patient with presumed toxoplasma encephalitis with a non-diagnostic brain biopsy. Graus et al 4 also identified only one patient with toxoplasma encephalitis from 425 patients who had undergone BMT. Another large study was performed by Slavin et al 20 who found 12 patients with toxoplasmosis of different organs out of 3294 patients after allogeneic BMT. Two of these patients had toxoplasma encephalitis confirmed by brain biopsy and responded to therapy with pyrimethamine and sulfadiazine, but died later from leukemia relapse. There are a few more single case reports, demonstrating cerebral toxoplasmosis in patients Figure 3 Cerebral toxoplasmosis with hemorrhage. Non-enhanced axial T1WI demonstrates a diffuse left temporal lesion (large arrow) and multiple small lesions (small arrows) with high signal (a). Postcontrast T1WI shows slight enhancement adjacent to the larger lesion (arrow, b). Hemorrhage was confirmed by computed tomography (c).
after BMT. 21, 22 However, in an autopsy study performed from 1972 to 1993 at our university, Schwechheimer et al 23 found six patients with toxoplasma encephalitis out of nine with severe neuropathological problems after BMT. One reason for the different frequency of toxoplasma encephalitis in comparison to studies which were performed in the USA [1] [2] [3] 6, 20 might be the high endemicity of toxoplasmosis reflected by seropositivity of the general population of 70-96% in Germany and much of Europe 24 in contrast to the USA of 3-68%. 24, 25 Another explanation for the common finding of toxoplasma encephalitis in our study may be the improvement in neuroradiological diagnosis techniques in comparison to former studies without MRI in some of their patients. 20 The neuroradiological findings of cerebral toxoplasmosis on computer tomographic images (CT) typically consists of multiple areas of iso-or hypodensity with ring or nodular enhancement on postcontrast CT. 26, 27 On T2-weighted images, lesions are usually hyperintense. On T1-weighted images lesions show iso-or hypointensity. After application of gadolinium MRI reveals ring or nodular enhancement, which is clearly distinguishable from surrounding edema. 26, 28, 29 The MRI appearance in the second group of patients with toxoplasma encephalitis in our population was similar to the characteristic findings in MRI as Table 6 Comparison of the two different groups of toxoplasma encephalitis defined as differences in MR appearance MR = magnet resonance; Gd = gadolinium; I-BMT = interval between BMT and CNS infection in days; ATG = antithymocyte globulin, OKT = monoclonal antibodies, mean corticosteroids = prednisone (mg) + [methyprednisolone (mg) ϫ 1.25]/n; * = significant. described above with the following exception: half of the patients in the second group had hyperintense lesions on MRI on non-enhanced T1-weighted images, suspicious of hemorrhagic transformation in these lesions. This could be verified on corresponding CT scans in one patient. Even though hemorrhage in toxoplasma lesions is uncommon, it has been reported. 20, 29 Most neuroradiological toxoplasma studies have been carried out in patients with AIDS. [26] [27] [28] In view of the fact that in that situation toxoplasma encephalitis seemed rare in patients after BMT little was known about the typical MRI appearance in these patients. One important difference from patients with AIDS is the usually significant reduction in white cells, red cells and platelets after BMT. The reduction in platelet numbers may lead to more frequent hemorrhage in toxoplasma lesions in patients after BMT in comparison to the findings in patients with AIDS.
In contrast to group two patients with toxoplasma encephalitis the MRI appearance in group one patients was dissimilar to the characteristic MRI features in cerebral toxoplasmosis usually described. In this group MRI imaging revealed only hyperintense lesions in T2-weighted images, localized to subcortical white matter, basal ganglia and cerebellum. In all seven patients in this group we failed to identify MRI features characteristic of CMV encephalitis, eg contrast-enhancing lesions in the subependymal and cortical regions, periventricular rarefaction or progressive ventriculomegaly. 30, 31 In addition, the pp65-antigen, PCR of herpes-simplex-and varicella-zoster-virus DNA, candida antigen and aspergillus antigen were negative at the time of infection and later on. All patients were positive for IgG antibodies against toxoplasmosis prior to transplant or at the time of infection, so that most of the reported cases of encephalitis were attributed to reactivation, even though toxoplasmosis could have been acquired from donor marrow. 32 No serologic test seemed particularly useful in the diagnosis of toxoplasma infection after BMT in former studies 20 or in the present study. Besides MRI appearances there were other differences between groups one and two with toxoplasma encephalitis (shown in Table 6 ). The most important difference was the lower leukocyte count in group one patients. A previous study also reported lack of contrast enhancement in brain parenchymal toxoplasma infection in patients with low leukocyte counts after BMT. 33 They explained their findings as a reduced inflammatory response due to neutropenia. This might be also an explanation for the lack of contrast-enhancement in the group one patients in the present study.
In summary, severe GVHD and use of high doses of immunosuppressive drugs were risk factors for developing toxoplasma encephalitis in the first 3 months after BMT. The strong association between toxoplasmosis and GVHD and its treatment has also been observed by others. 20, [34] [35] [36] [37] Early toxoplasma encephalitis was associated with a higher mortality than infection occurring later in the course of illness.
Aspergillus and candida encephalitis showed similar clinical features and MRI appearances, as described in former studies. [38] [39] [40] In immunocompromised patients aspergillus encephalitis occurs as part of a disseminated infection and invasive aspergillosis is an important cause of death from infection, 41 as confirmed in the present study. We found a mortality of 100% in accordance with former studies. 4, [38] [39] [40] [41] In conclusion, the present study showed toxoplasma encephalitis as the major cause of opportunistic CNS infection after allogeneic BMT. There were two types of toxoplasma encephalitis, which differed in time of onset after BMT, clinical and neuroradiological features and mortality. Risk factors for the occurrence of the early onset cerebral toxoplasmosis were severe GVHD and use of high-dose immunosuppression. Because of the nebulous value of serologic tests 20 and uncertain diagnostic value of PCR 42 in detection of toxoplasma infection, MR imaging should be performed as early as possible after development of neurological signs and specific treatment should be started as soon as toxoplasma encephalitis is suspected.
